Biological and pharmacological aspects of borderline personality disorder.
Biological and psychopharmacological research focusing on patients with a DSM-III-R diagnosis of borderline personality disorder suggests that the disorder may encompass three clusters of symptoms--affective instability, transient psychotic phenomena, and impulsive aggressive behavior--that have different underlying biological substrates that respond to different classes of pharmacological agents. Affective instability, which may be related to abnormalities in the brain's adrenergic and cholinergic systems, appears to respond to agents such as lithium and carbamazepine that are effective in treating major affective disorders. Abnormalities in central dopaminergic systems may underlie transient psychotic symptoms. This relationship is consistent with reports of beneficial effects of low-dose neuroleptics in treating some borderline patients. Abnormalities in central nervous system serotonergic functioning appear to underlie impulsive aggressive behaviors. These behaviors may respond to serotonergic agents such as fluoxetine.
Department of Psychiatry Medical College of Pennsylvania, Philadelphia 19129.
E F
EF
Coccaro
R J
RJ
Kavoussi
D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology
D018377:Neurotransmitter Agents; D011619:Psychotropic Drugs; D017981:Receptors, Neurotransmitter